Sagimet Biosciences (SGMT) Income towards Parent Company (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Income towards Parent Company of -$13.8 million for Q1 2026, up 30.91% year-over-year from -$10.6 million in Q1 2025, and down 3.37% quarter-over-quarter from -$13.4 million in Q4 2025.
Sagimet Biosciences (SGMT) Income towards Parent Company (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Income towards Parent Company history runs 5 years deep, the most recent figure standing at -$13.8 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 30.91% year-over-year to -$13.8 million; the TTM figure through Mar 2026 stood at -$69.9 million (up 46.13% YoY), while the FY2025 annual figure was -$54.8 million, up 51.02% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$13.8 million, down from -$13.4 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$6.7 million in Q1 2023, with the low at -$82.6 million in Q4 2024.
- The 5-year median for Income towards Parent Company is -$15.1 million (2024), against an average of -$21.8 million.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company tumbled 657.31% in 2024, then surged 83.82% in 2025.
- Sagimet Biosciences' Income towards Parent Company stood at -$55.0 million in 2022, then soared by 80.18% to -$10.9 million in 2023, then sank by 657.31% to -$82.6 million in 2024, then soared by 83.82% to -$13.4 million in 2025, then declined by 3.37% to -$13.8 million in 2026.
- Business Quant data shows SGMT's Income towards Parent Company at -$13.8 million in Q1 2026, -$13.4 million in Q4 2025, and -$20.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.88 Mn |
| Mar 31, 2026 | -13.82 Mn |
| Dec 31, 2025 | -13.37 Mn |
| Sep 30, 2025 | -19.96 Mn |
| Jun 30, 2025 | -22.74 Mn |
| Mar 31, 2025 | -20.00 Mn |
| Dec 31, 2024 | -82.59 Mn |
| Sep 30, 2024 | -16.44 Mn |
| Jun 30, 2024 | -10.67 Mn |
| Mar 31, 2024 | -8.80 Mn |
| Dec 31, 2023 | -10.91 Mn |
| Sep 30, 2023 | -24.09 Mn |
| Jun 30, 2023 | -28.36 Mn |
| Mar 31, 2023 | -6.69 Mn |
| Dec 31, 2022 | -55.03 Mn |
| Sep 30, 2022 | -7.47 Mn |
| Jun 30, 2022 | -7.34 Mn |